Patient Square Capital LP
Clone Performance
Sep 2023–Sep 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends. Returns are unavailable when a held security or benchmark crosses a captured split without a certified price basis; the requested window is not shortened to hide it. It tracks 100% of reported value on average across 13 quarters. Past performance does not predict future results.
Portfolio Concentration
23 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $645,523,808 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | +1,600,000 | 5,050,000 | $10,504,000 | |
| DBVT | DBV Technologies S.A. | +215,940 | 909,474 | $14,915,373 | |
| PHVS | Pharvaris N.V. | +178,209 | 671,209 | $23,210,407 | |
| RCUS | Arcus Biosciences, Inc. | +160,800 | 355,800 | $10,969,314 | |
| ABVX | Abivax S.A. | +85,255 | 206,500 | $27,518,190 | |
| MIRM | Mirum Pharmaceuticals, Inc. | +30,500 | 260,500 | $30,496,735 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | +14,118 | 108,000 | $10,527,840 | |
| ELVN | Enliven Therapeutics, Inc. | +12,500 | 212,500 | $10,784,375 | |
| ONC | BeOne Medicines Ltd. | +9,478 | 90,020 | $25,652,999 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| COGT | Cogent Biosciences, Inc. | −171,000 | 425,000 | $16,447,500 | |
| ROIV | Roivant Sciences Ltd. | −145,119 | 8,020,928 | $283,860,641 | |
| EYPT | EyePoint, Inc. | −75,000 | 720,000 | $10,296,000 | |
| KYMR | Kymera Therapeutics, Inc. | −52,500 | 47,500 | $5,446,825 | |
| ARQT | Arcutis Biotherapeutics, Inc. | −30,645 | 370,000 | $9,701,400 | |
| ARGX | Argenx SE | −13,718 | 23,000 | $21,338,710 | |
| XENE | Xenon Pharmaceuticals Inc. | −7,000 | 220,000 | $13,279,200 | |
| BLTE | Belite Bio, Inc | −6,684 | 110,000 | $16,938,350 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | 276,000 | $51,689,280 | |
| UTHR | UNITED THERAPEUTICS Corp | 37,120 | $20,112,729 | |
| BNTX | BioNTech SE | 134,429 | $12,508,618 | |
| CCCC | C4 Therapeutics, Inc. | 1,608,815 | $7,513,166 | |
| IVA | Inventiva S.A. | 1,967,171 | $7,435,906 | |
| FTH | Faeth Therapeutics, Inc. | 175,050 | $4,376,250 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| INSM | INSMED Inc | 157,500 | $25,754,400 | |
| LEGN | Legend Biotech Corp | 990,000 | $17,909,100 | |
| NKTR | Nektar Therapeutics | 210,000 | $15,109,500 | |
| CELC | Celcuity Inc. | 95,000 | $10,843,300 | |
| MRK | Merck & Co., Inc. | 80,000 | $9,623,200 | |
| CATX | Perspective Therapeutics, Inc. | 1,625,000 | $6,776,250 | |
| DFTX | Definium Therapeutics, Inc. | 331,000 | $6,255,900 | |
| HROW | Harrow, Inc. | 165,209 | $5,825,269 | |
| TARA | Protara Therapeutics, Inc. | 1,030,846 | $5,370,707 | |
| CTMX | CytomX Therapeutics, Inc. | 1,085,790 | $5,103,213 | |
| ASMB | Assembly Biosciences, Inc. | 136,315 | $3,782,741 | |
| SYRE | Spyre Therapeutics, Inc. | 1,000 | $50,440 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ROIV |
Roivant Sciences Ltd.
Healthcare
|
Reduced | 8,020,928 | $283,860,641 | 43.97% | |
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
NEW | 276,000 | $51,689,280 | 8.01% | |
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
Added | 260,500 | $30,496,735 | 4.72% | |
| ABVX |
Abivax S.A.
Healthcare
|
Added | 206,500 | $27,518,190 | 4.26% | |
| ONC |
BeOne Medicines Ltd.
Healthcare
|
Added | 90,020 | $25,652,999 | 3.97% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
Added | 671,209 | $23,210,407 | 3.60% | |
| ARGX |
Argenx SE
Healthcare
|
Reduced | 23,000 | $21,338,710 | 3.31% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
NEW | 37,120 | $20,112,729 | 3.12% | |
| BLTE |
Belite Bio, Inc
Healthcare
|
Reduced | 110,000 | $16,938,350 | 2.62% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 425,000 | $16,447,500 | 2.55% | |
| DBVT |
DBV Technologies S.A.
Healthcare
|
Added | 909,474 | $14,915,373 | 2.31% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Reduced | 220,000 | $13,279,200 | 2.06% | |
| BNTX |
BioNTech SE
Healthcare
|
NEW | 134,429 | $12,508,618 | 1.94% | |
| RCUS |
Arcus Biosciences, Inc.
Healthcare
|
Added | 355,800 | $10,969,314 | 1.70% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Added | 212,500 | $10,784,375 | 1.67% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Added | 108,000 | $10,527,840 | 1.63% | |
| ALLO |
Allogene Therapeutics, Inc.
Healthcare
|
Added | 5,050,000 | $10,504,000 | 1.63% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
Reduced | 720,000 | $10,296,000 | 1.59% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
Reduced | 370,000 | $9,701,400 | 1.50% | |
| CCCC |
C4 Therapeutics, Inc.
Healthcare
|
NEW | 1,608,815 | $7,513,166 | 1.16% | |
| IVA |
Inventiva S.A.
Healthcare
|
NEW | 1,967,171 | $7,435,906 | 1.15% | |
| KYMR |
Kymera Therapeutics, Inc.
Healthcare
|
Reduced | 47,500 | $5,446,825 | 0.84% | |
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 175,050 | $4,376,250 | 0.68% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.